2[1]Walsh TJ, Groll AH. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty - first centry. Transplant Infenct Dis, 1999, 1 (4): 247
3[5]Kanffman CA, Carver PL. Antifungal agents in the 1990s. Current status and future developments. Drugs, 1997 , 53 (4): 539
4[6]Develoux M. [Griseofulvin] . Ann Dermatol Venereol, 2001,128 (12:1317
5[7]Katz HI. Drug interactions of the newer oral antifungal agents. Br J Dermatol, 1999, 141 ( Suppl 56: 26
6[8]Anaissie, E. J., S. E. Vartivarian, D. Abi- Said, O. Uzun,H. Pinczowski, D.P. Kontoyiannis, P. Khoury, K. Papadakis,A. Gardner, I. I. Raad, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am. J. Med, 1996, 101:170
7[10]Johnson MD, Perfect JR. Caspofungin: first approved agent in a new class of antifungals. Expert Opin Pharmacother, 2003, 4(5): 807
8[11]Ullmann AJ. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole.Curr Med Res Opin, 2003, 19 (4): 263
